Compare AbbVie Inc (ABBV) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? AbbVie Inc trades at $250.75 (market cap $439.59B), while Alnylam Pharmaceuticals, Inc. trades at $223 (market cap $29.97B). The key difference: AbbVie Inc is far larger — about 14.7× Alnylam Pharmaceuticals, Inc.'s market cap, and AbbVie Inc pays a 2.78% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | ALNY | |
|---|---|---|
Market Cap | $439.59B | $29.97B |
Sector | Health | Health |
52-Week High | $263.58 | $491.22 |
52-Week Low | $197.38 | $205.48 |
Enterprise Value | $503.84B | $27.93B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 0.82% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth with Q2 2026 EPS beating expectations at $3.65 versus $3.61 estimate, while maintaining a 71.48% gross margin. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional accumulation signal confidence in the pipeline beyond Humira patent expiration.
AbbVie presents a compelling growth story with Skyrizi and Rinvoq driving revenue, though elevated P/E of 70.27 and patent cliff risks in the 2030s warrant caution. Analyst consensus remains strongly bullish with a $278.69 price target, representing 11.5% upside potential from current levels, supported by dividend growth and successful portfolio renewal.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
